Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer׳s disease

Gene therapy represents a promising treatment for the Alzheimer׳s disease (AD). However, gene delivery specific to brain lesions through systemic administration remains big challenge. In our previous work, we have developed an siRNA nanocomplex able to be specifically delivered to the amyloid plaque...

Full description

Saved in:
Bibliographic Details
Main Authors: Qian Guo (Author), Xiaoyao Zheng (Author), Peng Yang (Author), Xiaoying Pang (Author), Kang Qian (Author), Pengzhen Wang (Author), Shuting Xu (Author), Dongyu Sheng (Author), Liuchang Wang (Author), Jinxu Cao (Author), Wei Lu (Author), Qizhi Zhang (Author), Xinguo Jiang (Author)
Format: Book
Published: Elsevier, 2019-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_bb849093345041d0b3fd7ec9bb9ad94e
042 |a dc 
100 1 0 |a Qian Guo  |e author 
700 1 0 |a Xiaoyao Zheng  |e author 
700 1 0 |a Peng Yang  |e author 
700 1 0 |a Xiaoying Pang  |e author 
700 1 0 |a Kang Qian  |e author 
700 1 0 |a Pengzhen Wang  |e author 
700 1 0 |a Shuting Xu  |e author 
700 1 0 |a Dongyu Sheng  |e author 
700 1 0 |a Liuchang Wang  |e author 
700 1 0 |a Jinxu Cao  |e author 
700 1 0 |a Wei Lu  |e author 
700 1 0 |a Qizhi Zhang  |e author 
700 1 0 |a Xinguo Jiang  |e author 
245 0 0 |a Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer׳s disease 
260 |b Elsevier,   |c 2019-05-01T00:00:00Z. 
500 |a 2211-3835 
500 |a 10.1016/j.apsb.2018.12.010 
520 |a Gene therapy represents a promising treatment for the Alzheimer׳s disease (AD). However, gene delivery specific to brain lesions through systemic administration remains big challenge. In our previous work, we have developed an siRNA nanocomplex able to be specifically delivered to the amyloid plaques through surface modification with both CGN peptide for the blood-brain barrier (BBB) penetration and QSH peptide for β-amyloid binding. But, whether the as-designed nanocomplex could indeed improve the gene accumulation in the impaired neuron cells and ameliorate AD-associated symptoms remains further study. Herein, we prepared the nanocomplexes with an siRNA against β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), the rate-limiting enzyme of Aβ production, as the therapeutic siRNA of AD. The nanocomplexes exhibited high distribution in the Aβ deposits-enriched hippocampus, especially in the neurons near the amyloid plaques after intravenous administration. In APP/PS1 transgenic mice, the nanocomplexes down-regulated BACE1 in both mRNA and protein levels, as well as Aβ and amyloid plaques to the level of wild-type mice. Moreover, the nanocomplexes significantly increased the level of synaptophysin and rescued memory loss of the AD transgenic mice without hematological or histological toxicity. Taken together, this work presented direct evidences that the design of precise gene delivery to the AD lesions markedly improves the therapeutic outcome. KEY WORDS: siRNA delivery, Neurons, Amyloid plaques, BACE1 gene, Alzheimer׳s disease 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Acta Pharmaceutica Sinica B, Vol 9, Iss 3, Pp 590-603 (2019) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S221138351830532X 
787 0 |n https://doaj.org/toc/2211-3835 
856 4 1 |u https://doaj.org/article/bb849093345041d0b3fd7ec9bb9ad94e  |z Connect to this object online.